PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515297-27-00

Acronym

PRODIGE 70

Enrollment

142

Registered

2024-08-14

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon carcinoma

Brief summary

improve 3-year DFS from 25% to 42.5% by the use of adjuvant chemotherapy

Detailed description

Time to Recurrence (TTR), Overall Survival (OS), compare DFS and OS in ctDNA positive versus ctDNA negative patients,, toxicities using NCI-CTC v4 classification, success rate of prognostication of stage II colo-rectal cancer

Interventions

DRUGFLUOROURACILE TEVA 1000 mg/20 ml

DRUGsolution à diluer pour perfusion

DRUGFOLINIC ACID

DRUGELOXATINE 5 mg/ml

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
improve 3-year DFS from 25% to 42.5% by the use of adjuvant chemotherapy	—

Secondary

Measure	Time frame
Time to Recurrence (TTR), Overall Survival (OS), compare DFS and OS in ctDNA positive versus ctDNA negative patients,, toxicities using NCI-CTC v4 classification, success rate of prognostication of stage II colo-rectal cancer	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026